Sign up
Pharma Capital

Summit Therapeutics in a great position nearing the business end of its development

Glyn Edwards, chief executive of Summit Therapeutics PLC (LON:SUMM, NASDAQ:SMMT), caught up with Proactive Investors following the news they'd entered into a revenue sharing agreement with the Wellcome Trust for their ridinilazole drug for the treatment of clostridium difficile infection (CDI).

The deal follows a translational award (TA) funding agreement with the Wellcome Trust in October 2012, which provided funds for the Phase 1 and II clinical trials of ridinilazole that have since been completed.

Phase III clinical trials are scheduled to begin in the first half of 2018, the company said in a statement on Monday.

 

View full SUMM profile

Summit Therapeutics PLC Timeline

Newswire

Summit Therapeutics shares DMD data

View All

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.